Evolocumab and Alirocumab for treating dyslipidaemia

25th August 2016 by Louise Hudman

Evolocumab and Alirocumab for treating dyslipidaemia

There are two new guidelines from NICE on the use of Evolocumab and Alirocumab for treating primary hypercholesterolaemia (both familial and non-familial) and mixed dyslipidaemia.

What are these drugs?

  • Both Evolocumab and Alirocumab are monoclonal antibodies that inhibit an enzyme that down-regulates LDL receptors. This therefore increases the number of LDL receptors and so increases LDL uptake and reduces plasma LDL levels.
  • They are given by subcutaneous injection.
  • In most patients, they will be used in triple therapy with statins and ezetimibe. They can be used with just statins, or just with ezetimibe or other lipid lowering drugs. They can also be used alone.

When can they be used?

Evolocumab comes in 2 doses, but only the 140mg every 2 weeks dose is recommended (the higher dose is not cost-effective enough). Alirocumab comes in 75 or 150mg doses and both can be used.

They can be used when LDL levels are persistently above those specified below, despite maximum tolerated lipid-lowering therapy.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"The NASGP and the GP locum chambers that I'm in have provided invaluable assistance both before and through Covid-19 to me as a full-time GP locum. All aspects of locum work have been made easier as a result of membership and the chamber's support structure - from accessing work, to ensuring invoicing and documentation is all sorted, and access to other locums as peer support. Having a chamber manager means I feel more secure and can devote more of my energy on my clinical work."

Dr Richard Smith

Dr Richard Smith

See the full list of features within our NASGP membership plans

Membership